Intra-arterial Treatment for Liver Metastases in Colorectal Cancer
Author Information
Author(s): Cyjon A, Neuman-Levin M, Rakowsky E, Greif F, Belinky A, Atar E, Hardoff R, Brenner B, Sulkes A
Primary Institution: Beilinson Campus, Rabin Medical Center, Tel Aviv University
Hypothesis
Can intra-arterial chemotherapy improve response rates and survival in patients with liver metastases from colorectal cancer who have failed systemic treatment?
Conclusion
Intra-arterial treatment can lead to a significant response in patients with liver metastases from colorectal cancer who did not respond to standard chemotherapy.
Supporting Evidence
- 48% of patients achieved a major response to the treatment.
- The median duration of response was 11.5 months.
- Median survival was 12 months at a median follow-up of 12 months.
- Toxicity was moderate with 29% experiencing grades III–IV neutropenia.
Takeaway
Doctors tried a new way to give medicine directly to the liver for patients with cancer that didn't get better with regular treatment, and many patients felt better.
Methodology
Patients received a median of 5 cycles of intra-arterial chemotherapy with specific drug dosages over 5 consecutive days.
Limitations
The study had a small sample size and focused only on patients with liver disease.
Participant Demographics
Patients with hepatic metastases of colorectal origin who were refractory to standard systemic treatment.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website